Regeneron Pharmaceuticals (REGN) Financials

$827.72

$-24.31 (-2.85%)

As on 04-Sep-2026 16:15EDT

Market cap

$85,218 Mln

Revenue (TTM)

$15,535 Mln

P/E Ratio

20.9

P/B Ratio

2.8

Div. Yield

0.4 %

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Operating Revenue	15,534.70	14,342.90	14,202.00	13,117.20	12,172.90	16,071.70
Cost of Revenue	2,352.10	2,100.70	1,970.50	883.70	1,705.20	2,723.70
Gross Profit	13,182.60	12,242.20	12,231.50	12,233.50	10,467.70	13,348.00
Operating Expenses	9,212.50	8,664.30	8,240.80	7,070.30	5,082.10	4,401.20
Operating Profit (EBIT)	3,970.10	3,577.90	3,990.70	4,047.10	5,385.60	8,946.80
Other Income	--	--	--	--	179.30	436.30
Profit before Tax	5,166.00	5,230.70	4,779.90	4,199.30	4,858.80	9,325.80
Provision for Tax	837.30	725.80	367.30	245.70	520.40	1,250.50
Profit after Tax (Net Income)	4,328.70	4,504.90	4,412.60	3,953.60	4,338.40	8,075.30
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	4,338.40	8,075.30

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Shareholder's Funds	31,711.00	31,256.90	29,353.60	25,973.10	22,664.00	18,768.80
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	4,488.60	4,933.40	4,461.50	3,683.70	3,409.20	2,733.50
Current Liabilities	5,530.60	4,368.40	3,944.30	3,423.40	3,141.30	3,932.50
Total Liabilities	47,260.60	40,558.70	37,759.40	33,080.20	29,214.50	25,434.80

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Non-Current Assets	23,284.00	22,536.80	19,098.50	13,601.00	13,330.40	11,419.90
Current Assets	18,446.00	18,021.90	18,660.90	19,479.20	15,884.10	14,014.90
Total Assets	47,260.60	40,558.70	37,759.40	33,080.20	29,214.50	25,434.80
Total Debt*	1,986.60	2,705.90	2,704.40	2,702.90	2,701.40	2,699.70
Net Current Assets	12,915.40	13,653.50	14,716.60	16,055.80	17,495.60	17,069.50

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Cash From Operating Activities	--	4,978.90	4,420.50	4,594.00	5,014.90	7,081.30
Cash Flow from Investing Activities	--	-629.10	-2,468.10	-3,185.10	-3,784.60	-5,384.70
Cash from Financing Activities	--	-3,715.40	-2,200.50	-1,790.10	-1,009.00	-1,005.80
Net Cash Inflow / Outflow	--	--	--	--	221.30	690.80

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Adjusted EPS ($)	40.37	41.91	38.78	34.74	38.06	71.34
Cash EPS ($)	--	46.96	43.02	38.33	41.05	73.86
Adjusted Book Value ($)	--	290.76	257.94	228.23	198.81	165.80
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	46.32	38.84	40.37	43.99	62.56
Free Cash Flow per Share ($)	--	37.96	32.20	32.23	38.81	57.68

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
ROCE (%)	--	13.65	14.53	14.63	18.53	44.73
ROE (%)	13.75	14.87	15.95	16.26	20.94	54.21
ROA (%)	9.71	11.50	12.46	12.69	15.88	37.91
EBIT Margin (%)	33.61	36.77	34.05	30.85	40.40	58.38
Net Margin (%)	27.86	31.41	31.07	30.14	35.12	48.92
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Revenue Growth (%)	9.29	0.01	0.08	0.08	-0.24	0.89
EBIT Growth (%)	6.31	9.09	19.47	-17.71	-47.58	142.63
Net Profit Growth (%)	-2.91	2.09	11.61	-8.87	-46.28	129.86
EPS Growth (%)	1.72	0.08	0.12	-0.09	-0.47	1.28
Book Value Growth (%)	7.70	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Price / Earnings	20.88	18.42	18.37	25.31	18.96	8.85
Price / Book Value	2.77	2.65	2.76	3.85	3.63	3.81
Dividend Yield (%)	0.43	--	--	--	--	--
EV/EBITDA	14.34	13.25	14.06	22.71	14.68	7.08
Close Price ($)	623.54	771.87	712.33	879.17	721.49	631.52
High Price ($)	821.11	792.77	1,211.20	899.85	779.00	686.62
Low Price ($)	521.00	476.49	693.00	668.00	538.01	441.00
Market Cap ($ Cr)	85,217.90	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debt to Equity	0.06	0.09	0.09	0.10	0.12	0.14
Short term debt to equity ratio	--	0.00	--	--	0.03	0.04
Current Ratio	3.34	4.13	4.73	5.69	5.06	3.56
Quick Ratio	2.78	3.39	3.95	4.94	4.29	3.07
Interest Coverage	94.25	120.42	87.59	55.44	82.80	163.75

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debtors to sales (%)	42.26	40.03	43.74	43.21	43.78	37.56
Asset Turnover	0.35	0.37	0.40	0.42	0.45	0.75
Receivable days	--	152.19	152.76	153.09	170.51	115.35
Inventory Days	--	546.66	525.29	1,029.66	466.22	259.34
Payable days	--	150.27	129.39	247.12	123.51	69.70
Cash Conversion Cycle	--	548.59	548.65	935.63	513.22	304.99

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Income Statement ($ Mln)